Abstract
Angiotensin converting enzyme (ACE) 2 is a homologue of ACE that catalyzes the conversion of Angiotensin (Ang) II into Ang1-7, which induces vasodilation, anti-fibrotic, anti-proliferative and anti-inflammatory effects. Given that ACE2 counterbalances the effects of Ang II, it has been proposed as a biomarker in kidney disease patients. Circulating ACE2 has been studied in human and experimental studies under physiological and pathological conditions and different techniques have been assessed to determine its enzymatic activity. In patients with cardiovascular (CV) disease circulating ACE2 has been shown to be increased. In addition, hypertensive and diabetic patients have also shown higher circulating ACE2 activities. A study in type 1 diabetes patients found a negative association between circulating ACE2 and estimated glomerular filtration rate in male and female patients. Recently, it has been demonstrated that circulating ACE2 is increased in male patients with chronic kidney disease (CKD) and that it is independently associated with other classical CV risk factors, such as advanced age and diabetes. Furthermore, circulating ACE2 has been shown to be associated with silent atherosclerosis and CV outcomes in CKD patients. In diabetic nephropathy, experimental studies have demonstrated an increase in circulating ACE2 activity both at early and late stages of the disease, as well as a direct association with increased urinary albumin excretion, suggesting that it may be increased as a renoprotective mechanism in these patients. In this paper we will review the measurement of circulating ACE2 and its role in kidney disease, as well as its potential role as a renal and CV biomarker.
Keywords: Angiotensin-converting enzyme 2, Chronic kidney disease, Cardiovascular disease, Biomarker, Reninangiotensin system, diabetes.
Current Medicinal Chemistry
Title:Circulating ACE2 in Cardiovascular and Kidney Diseases
Volume: 24 Issue: 30
Author(s): L. Anguiano, M. Riera , J. Pascual and M. J. Soler*
Affiliation:
- Department of Nephrology, Hospital del Mar, Passeig Maritim 25-29, 08003 Barcelona,Spain
Keywords: Angiotensin-converting enzyme 2, Chronic kidney disease, Cardiovascular disease, Biomarker, Reninangiotensin system, diabetes.
Abstract: Angiotensin converting enzyme (ACE) 2 is a homologue of ACE that catalyzes the conversion of Angiotensin (Ang) II into Ang1-7, which induces vasodilation, anti-fibrotic, anti-proliferative and anti-inflammatory effects. Given that ACE2 counterbalances the effects of Ang II, it has been proposed as a biomarker in kidney disease patients. Circulating ACE2 has been studied in human and experimental studies under physiological and pathological conditions and different techniques have been assessed to determine its enzymatic activity. In patients with cardiovascular (CV) disease circulating ACE2 has been shown to be increased. In addition, hypertensive and diabetic patients have also shown higher circulating ACE2 activities. A study in type 1 diabetes patients found a negative association between circulating ACE2 and estimated glomerular filtration rate in male and female patients. Recently, it has been demonstrated that circulating ACE2 is increased in male patients with chronic kidney disease (CKD) and that it is independently associated with other classical CV risk factors, such as advanced age and diabetes. Furthermore, circulating ACE2 has been shown to be associated with silent atherosclerosis and CV outcomes in CKD patients. In diabetic nephropathy, experimental studies have demonstrated an increase in circulating ACE2 activity both at early and late stages of the disease, as well as a direct association with increased urinary albumin excretion, suggesting that it may be increased as a renoprotective mechanism in these patients. In this paper we will review the measurement of circulating ACE2 and its role in kidney disease, as well as its potential role as a renal and CV biomarker.
Export Options
About this article
Cite this article as:
Anguiano L., Riera M. , Pascual J. and Soler J. M.*, Circulating ACE2 in Cardiovascular and Kidney Diseases, Current Medicinal Chemistry 2017; 24 (30) . https://dx.doi.org/10.2174/0929867324666170414162841
DOI https://dx.doi.org/10.2174/0929867324666170414162841 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk
Current Vascular Pharmacology Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Prolylcarboxypeptidase Gene Expression in the Heart and Kidney: Effects of Obesity and Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Incidence of Type 2 Diabetes Among Patients Exposed to the Combination of Pravastatin and Paroxetine
Current Drug Safety Gastric Bypass and Diabetes: Past, Present and Future
Current Diabetes Reviews Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy
Mini-Reviews in Medicinal Chemistry Bioaccessibility of Bioactive Compounds and Prebiotic Properties of Fruit and Vegetable By-products - A Mini Review
Current Bioactive Compounds Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach
Current Medicinal Chemistry Development of Inhibitors of the Aspartyl Protease Renin for the Treatment of Hypertension
Current Protein & Peptide Science Peptide Metabolism and the Control of Body Fluid Homeostasis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Current Pharmaceutical Design JAK3 Inhibitors in Organ Transplantation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Is There an Association between Periodontitis and Hypertension?
Current Cardiology Reviews Angiotensin II Blockade and Renal Protection
Current Pharmaceutical Design Usefulness of Home Blood Pressure in the Diagnosis and Control of Hypertension in Primary Care
Current Hypertension Reviews Aliskiren in Patients with Diabetes: A Systematic Review
Current Vascular Pharmacology Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Capillary Electrophoresis Interfaced with a Mass Spectrometer (CE-MS): Technical Considerations and Applicability for Biomarker Studies in Animals
Current Protein & Peptide Science